We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · December 13, 2021

Brain Metastases in EGFR- and ALK-Positive NSCLC

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation
J Thorac Oncol 2021 Aug 26;[EPub Ahead of Print], NJ Thomas, NJ Myall, F Sun, T Patil, R Mushtaq, C Yu, S Sinha, EL Pollom, S Nagpal, DR Camidge, CG Rusthoven, SE Braunstein, HA Wakelee, CE McCoach

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading